Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-26T21:28:17.443Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluation of 18fluoro-2-deoxyglucose positron emission tomography in iodine scan negative, differentiated thyroid cancer recurrence

Published online by Cambridge University Press:  16 July 2009

E J Chisholm  and
N S Tolley
E J Chisholm*
Affiliation:
Department of ENT, St Mary's Hospital, Imperial College Hospitals NHS Trust, London, UK
N S Tolley
Affiliation:
Department of ENT, St Mary's Hospital, Imperial College Hospitals NHS Trust, London, UK
*
Address for correspondence: Mr E Chisholm, 44 Eastbury Grove, London W4 2JY, UK. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Follow up of patients with differentiated thyroid cancer is based upon anatomical imaging, thyroglobulin assay and functional imaging in the form of iodine uptake scanning. A significant cohort of such patients have rising thyroglobulin levels but negative iodine scans. In this group, 18fluoro-2-deoxyglucose positron emission tomography scans have been commonly employed. The aim of this study was to assess the usefulness of such investigation.

Methods:

The sensitivity of 18fluoro-2-deoxyglucose positron emission tomography for detecting recurrence of differentiated thyroid cancer was calculated from a retrospective review of scan results from patients with iodine scan negative recurrence.

Results:

Eighteen patients with rising thyroglobulin levels underwent 18fluoro-2-deoxyglucose positron emission tomography scanning. Fourteen patients had negative (and four equivocal) whole body iodine scintigraphy scans. Of these 14, six patients had a positive 18fluoro-2-deoxyglucose positron emission tomography scan, giving a sensitivity of 42.9 per cent.

Conclusions:

When assessed in the clinical setting and restricted to patients with negative iodine scans, the sensitivity of 18fluoro-2-deoxyglucose positron emission tomography was found to be lower than in previous case series.

Keywords

Thyroid NeoplasmsPositron Emission Tomography
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 10 , October 2009 , pp. 1145 - 1149
Copyright
Copyright © JLO (1984) Limited 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1UK Thyroid Cancer Statistics 2004. In: http://info.cancerresearchuk.org/cancerstats/types/thyroid/incidence/ [May 2008]Google Scholar
2Mazzaferri, EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421–7CrossRefGoogle ScholarPubMed
3British Thyroid Association. Guidelines for the Management of Thyroid Cancer, 2nd edn. London: Royal College of Physicians, 2007;1–2Google Scholar
4British Thyroid Association. Guidelines for the Managment of Thyroid Cancer, 2nd edn. London: Royal College of Physicians, 2007;34Google Scholar
5Schlumberger, M, Pacini, F, Wiersinga, WM, Toft, A, Smit, JW, Sanchez Franco, F et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004;151:539–48CrossRefGoogle ScholarPubMed
6Mazzaferri, EL, Robbins, RJ, Spencer, CA, Braverman, LE, Pacini, F, Wartofsky, L et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433–41CrossRefGoogle ScholarPubMed
7Mirallie, E, Guillan, T, Bridji, B, Resche, I, Rousseau, C, Ansquer, C et al. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 2007;142:952–8CrossRefGoogle ScholarPubMed
8Zimmer, LA, McCook, B, Meltzer, C, Fukui, M, Bascom, D, Snyderman, C et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003;128:178–84CrossRefGoogle ScholarPubMed
9Finkelstein, SE, Grigsby, PW, Siegel, BA, Dehdashti, F, Moley, JF, Hall, BL. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 2008;15:286–92CrossRefGoogle ScholarPubMed
10Joensuu, H, Ahonen, A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910–14Google ScholarPubMed
11Wang, W, Larson, SM, Fazzari, M, Tickoo, SK, Kolbert, K, Sgouros, G et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107–13Google ScholarPubMed
12Khan, N, Oriuchi, N, Higuchi, T, Zhang, H, Endo, K. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003;76:690–5CrossRefGoogle ScholarPubMed
13Shiga, T, Tsukamoto, E, Nakada, K, Morita, K, Kato, T, Mabuchi, M et al. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001;42:414–19Google ScholarPubMed
14Feine, U, Lietzenmayer, R, Hanke, JP, Wohrle, H, Muller-Schauenburg, W. 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I [in German]. Nuklearmedizin 1995;34:127–34Google ScholarPubMed
15Isles, MG, McConkey, C, Mehanna, HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210–22CrossRefGoogle ScholarPubMed
16Alnafisi, NS, Driedger, AA, Coates, G, Moote, DJ, Raphael, SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010–15Google ScholarPubMed
17Alzahrani, AS, Mohamed, GE, Al Rifai, A, Al-Sugair, A, Abdel Salam, SA, Sulaiman, OM et al. Role of [18F]fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr Pract 2006;12:152–8CrossRefGoogle ScholarPubMed
18Chung, JK, So, Y, Lee, JS, Choi, CW, Lim, SM, Lee, DS et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999;40:986–92Google ScholarPubMed
19Conti, PS, Durski, JM, Bacqai, F, Grafton, ST, Singer, PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797–804CrossRefGoogle ScholarPubMed
20Dietlein, M, Scheidhauer, K, Voth, E, Theissen, P, Schicha, H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342–8CrossRefGoogle ScholarPubMed
21Frilling, A, Tecklenborg, K, Gorges, R, Weber, F, Clausen, M, Broelsch, EC. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804–11CrossRefGoogle ScholarPubMed
22Gabriel, M, Froehlich, F, Decristoforo, C, Ensinger, C, Donnemiller, E, von Guggenberg, E et al. 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging 2004;31:330–41CrossRefGoogle Scholar
23Giammarile, F, Hafdi, Z, Bournaud, C, Janier, M, Houzard, C, Desuzinges, C et al. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 2003;149:293–300CrossRefGoogle ScholarPubMed
24Goshen, E, Cohen, O, Rotenberg, G, Oksman, Y, Karasik, A, Zwas, ST. The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma. Nucl Med Commun 2003;24:959–61CrossRefGoogle ScholarPubMed
25Grunwald, F, Kalicke, T, Feine, U, Lietzenmayer, R, Scheidhauer, K, Dietlein, M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547–52CrossRefGoogle ScholarPubMed
26Helal, BO, Merlet, P, Toubert, ME, Franc, B, Schvartz, C, Gauthier-Koelesnikov, H et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001;42:1464–9Google Scholar
27Nahas, Z, Goldenberg, D, Fakhry, C, Ewertz, M, Zeiger, M, Ladenson, PW et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005;115:237–43CrossRefGoogle ScholarPubMed
28Palmedo, H, Bucerius, J, Joe, A, Strunk, H, Hortling, N, Meyka, S et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616–24Google ScholarPubMed
29Schluter, B, Bohuslavizki, KH, Beyer, W, Plotkin, M, Buchert, R, Clausen, M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42:71–6Google ScholarPubMed
30Shammas, A, Degirmenci, B, Mountz, JM, McCook, BM, Branstetter, B, Bencherif, B et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007;48:221–6Google ScholarPubMed
31Stokkel, MP, de Klerk, JH, Zelissen, PM, Koppeschaar, HP, van Rijk, PP. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 1999;26:1606–9CrossRefGoogle ScholarPubMed
32Wang, W, Macapinlac, H, Larson, SM, Yeh, SD, Akhurst, T, Finn, RD et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291–302CrossRefGoogle ScholarPubMed
33Facey, K, Bradbury, I, Laking, G, Payne, E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007;11:44CrossRefGoogle ScholarPubMed